In cancer, both ERK and AKT signaling confer resistance to apoptosis via upregulation of a panel of anti-apoptotic proteins including MCL1, X-linked inhibitor of apoptosis protein (XIAP) and BCL-xL. This evidence concerns the gene BCL2L1 and cancer.